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The human PrP gene (PRNP) has two common alleles
that encode either methionine or valine at codon 129.
This polymorphism modulates disease susceptibility
and phenotype of human transmissible spongiform en-
cyphalopathies, but the molecular mechanism by which
these effects are mediated remains unclear. Here, we
compared the misfolding pathway that leads to the for-
mation of -sheet-rich oligomeric isoforms of the methi-
onine 129 variant of PrP to that of the valine 129 variant.
We provide evidence for differences in the folding be-
havior between the two variants at the early stages of
oligomer formation. We show that Met129 has a higher
propensity to form -sheet-rich oligomers, whereas
Val129 has a higher tendency to fold into -helical-rich
monomers. An equimolar mixture of both variants dis-
played an intermidate folding behavior. We show that
the oligomers of both variants are initially a mixture of
- and -rich conformers that evolve with time to an
increasingly homogeneous -rich form. This maturation
process, which involves no further change in proteinase
K resistance, occurs more rapidly in the Met129 form
than the Val129 form. Although the involvement of such
-rich oligomers in prion pathogenesis is speculative,
the misfolding behavior could, in part, explain the
higher susceptibility of individuals that are methionine
homozygote to both sporadic and variant Creutzfeldt-
Jakob disease.
The transmissible spongiform encephalopathies are a group
of fatal, neurodegenerative disorders that affect humans and
animals and are believed to be caused by a novel class of
infectious pathogen, the prion (1, 2). These diseases have at-
tracted considerable interest not only because of their unique
biology but also because of the appearance of new variant of
Creutzfeldt-Jakob disease (vCJD)1 (3), which appears to be
caused by dietary exposure to the causative agent of bovine
spongiform encephalopathy (4, 5). At the heart of disease
pathogenesis lies a poorly understood structural rearrange-
ment of PrP, a host-encoded glycoprotein of the nervous and
lymphoid systems. The normal cellular form of the prion pro-
tein (PrPC) undergoes a conversion that leads to the accumu-
lation of an abnormal, conformationally altered isoform
(PrPSc). According to the “protein-only” hypothesis of prion
propagation, PrPSc is the principal or sole component of trans-
missible prions (6). PrPSc differs from PrPC by increased
-sheet content, increased resistance to proteinase K, and an
oligomeric rather than a monomeric state (7).
The human PrP gene (PRNP) exists in two major allelic
forms that encode either methionine or valine at codon 129,
with allele frequencies of 0.63 and 0.37 in western European
and American populations, respectively (8, 9). This polymor-
phism is a key determinant of susceptibility to sporadic (10)
and acquired (8, 11) prion diseases and may affect age at onset
(12–14). Based on the analysis of 300 sporadic CJD subjects,
Parchi et al. (14) identified six distinct clinicopathological vari-
ants of sCJD, which appeared to be specified largely by the
genotype at codon 129 and the physiochemical properties of
PrPSc. More recently, an extensive analysis, which included the
metal ion-dependent conformation of PrPSc, of a large number
of sCJD cases showed that PrPSc types are associated with the
residue encoded at codon 129, the duration of illness, and with
neuropathological phenotype (15). PrPSc types 1 and 4 have so
far been detected only in Met129 homozygotes, type 4 being
uniquely associated with vCJD, type 3 in cases containing a
Val129 allele, and type 2 in any PRNP codon 129 genotype (16).
The codon 129 polymorphism seemed to modulate the pattern
of neuropathology and the extent of lesions in sCJD, as shown
in a study that involved 70 patients who died in France be-
tween 1994 and 1998 (17). Codon 129 polymorphism also has
epistatic effects on the phenotypic effects of mutations else-
where in the prion gene. For example, the Asp178 3 Gln mu-
tation combined with a methionine at position 129 results in
fatal familial insomnia (18). In contrast, the same mutation
with a valine encoded at position 129 results in familial CJD
(19). Similarly, Val129 homozygotes in association with the
Phe198 3 Ser mutation predispose patients to the Indiana
kindred variant of Gerstmann-Straussler-Scheinker disease
(20). Furthermore, an increased prevalence of genotype Val/Val
at the polymorphic site 129 has been described in patients with
early onset Alzheimer’s disease (21) and a shift in cognitive
decline toward early age in carriers of PRNP129 Val/Val has
been reported recently (22).
Despite the clear importance of the polymorphism at codon
129 in the PRNP gene and its link to disease susceptibility and
pathogenesis, the molecular mechanisms by which these effects
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are mediated remain unclear. The in vitro, thermodynamic
stability of recombinant PrP is not affected by the Met1293 Val
mutation or by other substitutions related to inherited human
prion diseases (23). Structural studies, however, have shown
evidence for hydrogen bonding between residues 128 and 178,
which might provide a structural basis for the highly specific
influence of polymorphism in position 129 on disease pheno-
type that segregates with Asp178 3 Gln (24). Molecular dy-
namic simulations of low pH-induced conformational conver-
sion of PrP has provided further clues as to the role of residue
129 (25). In these simulations, Met129 seems to interact with
Val122 leading to the recruitment of more N-proximal residues
into an expanding -sheet. As a complementary approach, we
have chosen to study the folding properties of the two PrP
allelomorphs experimentally by examining the misfolding
pathway that leads to the formation of -sheet-rich oligomeric
isoforms (26). We show that PrP-Met129 has a higher propen-
sity to form -sheet-rich oligomers, whereas PrP-Val129 has a
higher tendency to fold into -helical-rich monomers. We also
provide evidence that the dynamics of maturation of the oli-
gomers differ between the two variants. The maturation proc-
ess occurs over time at the expense of the -helical-like mono-
mers at a faster rate for PrP-Met129 than for PrP-Val129. Once
the oligomers from either allelomorph have been formed they
show similar proteinase K resistance that does not change
throughout the oligomer maturation process. The observed dif-
ferences in the misfolding of PrP-Met129 and PrP-Val129 could
explain the high susceptibility of individuals that are methio-
nine homozygote to sporadic as well as variant CJD.
MATERIALS AND METHODS
Cloning of PrP Genes and Protein Purification—Genomic DNA en-
coding methionine/valine at codon 129 of PRNP gene (18) was extracted
from the blood of a heterozygote individual using standard phenol-
chloroform methods. The fragment of the PRNP gene spanning codon
90 through 231 was amplified with the oligonucleotide primers 5-
cgggatcccatgcaaggaggtggcacccacagtcagtggaacaagccg-3 (and 5-cccaagct-
tcatgctcgatcctctctggtaataggcctgag-3 in 100 l of PCR buffer that con-
tained 300 ng of each DNA, 2 units of Taq DNA polymerase, 200 M
concentration of each dNTP, 0.2 M concentration each primer, 3.5 M
MgCl2, 10 mM Tris-HCl, pH 9.0, 0.1% Triton X-100, 50 mM KCl. The
following PCR conditions were used: an initial denaturation (95 °C, 3
min) followed by 25 cycles of denaturation (95 °C, 1 min), annealing
(55 °C, 1 min), extension (72 °C, 1 min), and a final elongation (72 °C, 8
min). Restriction sites BamHI and HindIII, including extra nucleotides
for efficient cleavage close to the ends, were introduced in the primers.
The PCR fragment was cloned into the pTrcHis2B vector that incorpo-
rated a C-terminal His tag (Invitrogen, Paisley, UK) according to the
manufacturer’s instructions. The identity of human PrP clones was
confirmed by sequencing with the BigDye Terminator v3.0 on ABI-
Prism 3100 Genetic Analyzer (Applied Biosystems). The clones corre-
sponding to PrP90–231 with Met129 or Val129 were identified by compar-
ison with human PrP clones available in the databases (GenBankTM
accession numbers: M13667 and P04156). Escherchia coli expression
and purification of recombinant human PrP was performed as described
previously (27) except that the buffer used to solubilize inclusion bodies
did not contain dithiothreitol. Stocks of highly purified proteins were
stored in 6 M guanidine hydrochloride, 50 mM Tris-HCl, pH 7.2.
Oligomer Formation by HPLC Gel Filtration and Dialysis Methods—
Rapid refolding of proteins into oligomeric isoforms was carried out at
concentrations of 10 and 30 mg/ml. PrP-Met129 and PrP-Val129 were
denatured in 6 M guanidine hydrochloride, 50 mM Tris-HCl, pH 7.2, and
were injected (100 l) onto a size exclusion chromatography (SEC)
column (TSK®-Gel SWXL G3000 HPLC column, 7.8  300 mm, Phe-
nomenex, Macclesfield, UK), equilibrated in 20 mM sodium acetate, 0.2
M NaCl, pH 3.7, 1 M urea, and 0.02% sodium azide (26). This rapid
oligomer formation on SEC-HPLC corresponded to time 0 as opposed to
time course analysis of oligomer formation during dialysis. This time
course analysis of oligomer formation was carried out as follows. 1 ml of
6 M guanidine hydrochloride-denatured proteins (10 or 30 mg/ml) was
dialyzed at room temperature against 2 liters of 20 mM sodium acetate,
0.2 M NaCl, pH 3.7, 2 M urea by use of a Slide-A-Lyser dialysis cassette
(Perbio Science UK Ltd., Tattenhall, UK) with a 10-kDa cutoff. Aliquots
were withdrawn, after carefully shaking the cassette to ensure homo-
geneity, after 30 min and 2, 4, and 24 h and analyzed by SEC as
described above. Protein peaks were manually collected for subsequent
analysis. Circular dichroism was carried as described previously (28) to
assess the secondary structure of the protein.
Analytical Reversed-phase HPLC—Protein fractions collected during
SEC analysis were kept in SEC elution buffer at room temperature and
analyzed after 2, 12, 30, 110, 140, 200, and 300 days by analytical
reversed-phase (RP) HPLC (Sephasil® C4, 5 m, 4.6  250 mm) (Am-
ersham Biosciences, Little Chalfont, UK). Proteins were eluted with a
linear gradient of H2O  0.1% trifluoroacetic acid to 95% acetonitrile 
0.09% trifluoroacetic acid over 25 min.
All HPLC separations were performed at room temperature with a
flow rate of 1 ml/min by means of a PerkinElmer Life Sciences HPLC
system composed of a Binary LC pump 250 and a diode array detector
235C controlled by Total Chrome software version 6.2 (PerkinElmer
Life Sciences, Seer Green, UK) through a PE Nelson 600 series link.
The eluent was monitored by UV absorption at 280 nm.
Proteinase K Digestion—Recombinant human PrP collected from
SEC-HPLC was subjected to proteinase K digestion after 2, 12, and 140
days maturation of the oligomers. The solution was incubated at 37 °C
with a ratio of 1:24 PK to protein in 20 mM sodium acetate, 0.2 M NaCl,
pH 5.5. Aliquots of the digests were taken after 15, 30 and 60 min and
snap-frozen for analysis by SDS-PAGE and mass spectrometry.
On-line Capillary HPLC Nanospray Mass Spectrometry—Mass spec-
trometry was carried out on a Quattro II tandem quadrupole mass
spectrometer (Micromass UK Ltd., Altrincham, UK) equipped with
on-line capillary HPLC as detailed in Ref. 29. Briefly, the capillary
HPLC was 180 m inner diameter and was packed with 3.5-m Jupiter
C18 resin (Phenomenex, Macclesfield, UK). A flow rate of 1 l/min was
used, and proteins were eluted with a gradient from 0–70% solvent A to
B, where solvent A was 95:5 water:acetonitrile with 0.05% trifluoroace-
tic acid, and solvent B was 95:5 water:acetonitrile with 0.05% trifluoro-
acetic acid. The eluent was passed directly to the mass spectrometer,
which was operated in continuous flow nanospray mode. Full scan mass
spectra (m/z 300–2100) were acquired every 5 s.
RESULTS
Characterization of Recombinant Human PrP-Met129 and
PrP-Val129—Recombinant human prion protein variants,
HuPrP90–231 Met129 and HuPrP90–231 Val129, were purified to
homogeneity by immobilized metal affinity chromatography
(see supplementary Fig. 1) followed by RP-HPLC. Purified
proteins were analyzed by mass spectrometry to confirm purity
and identity. Omitting dithiothreitol from the buffer used to
solubilize the inclusion bodies and allowing disulfide bond to
form in the oxidizing environment of the immobilized metal
affinity chromatography was found to yield a fully oxidized
protein (see supplementary Fig. 1) that has characteristics of
PrPC, such as a monomeric state, high -helical content, and
proteinase K sensitivity. All the studies presented in this paper
were performed on proteins that included a C-terminal His tag.
PrP-Met129 Has an Intrinsically Higher Propensity to Oli-
gomerize than PrP-Val129—To assess the effect of the codon 129
polymorphic residue on the formation of non-native isoforms,
both protein variants were denatured in 6 M guanidine hydro-
chloride, 50 mM Tris-HCl, pH 7.2, and allowed to fold under
conditions favoring the formation of -oligomer species (26). To
dissect the in vitro folding pathway of prion protein misfolding
we used SEC, dialysis, and CD. The denatured proteins (30
mg/ml) were injected onto a SEC column that had previously
been equilibrated in 20 mM sodium acetate, 0.2 M NaCl, pH 3.7,
1 M urea, and 0.02% sodium azide and eluted with the same
buffer. The elution profile of the Met129 variant shows two
major peaks and one minor peak (Fig. 1A). Peak I (terminology
as given by Baskakov et al. (26)) eluted at 5.68 min and corre-
sponded to high molecular weight aggregates (Fig. 1A). Peak II
eluted at 6.54 min and corresponded to the oligomeric isoform,
while peak III, which eluted at 9.08 min, had a similar reten-
tion time to monomeric protein (Fig. 1A). The elution profile of
Val129 variant shows the same three peaks but in different
proportions, with peak II eluting as a shoulder to peak I (Fig.
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1B). To mimic a heterozygote situation of an individual that
carries both alleles, we have analyzed the folding behavior in a
1:1 mixture of Met129 and Val129 (Fig. 1C). The elution profile
of the equimolar mixture showed three peaks as seen before
(Fig. 1C). Integration of the peaks in Fig. 1, A and B, revealed
that less than 2% of the Val129 variant had formed oligomers
under these rapid refolding conditions (within the first 10 min
of the SEC elution) as compared with more than 70% in the
case of Met129 (Fig. 1D). In addition, the percentage of mono-
meric population that was formed within 10 min was calculated
to be about 66% for the Val129 variant but only 24% for the
Met129 variant (Fig. 1D). Integration of the peaks in the
equimolar mixture showed that the percentage of oligomeric
form was reduced to about 44%, corresponding to 30% reduc-
tion in the amount of oligomers as compared with the situation
of the Met129 alone (Fig. 1D). Also the amount of the monomeric
population in the mixture 1:1 increased by about 17% when
compared with that of the Met129 alone (Fig. 1D). The mono-
meric forms of Met129 and Val129 variants yielded CD spectra
with two minima at 208 and 222 nm, indicative of a predomi-
nantly -helical conformation (data not shown). The CD spec-
tra of protein from peak II of PrP-Met129 and peaks I and II of
PrP-Val129 did not give clear information about the protein
conformations but suggested that these fractions were com-
posed of a mixture of -helical and -sheet forms.
To investigate the formation and evolution of the oligomers
that eluted in peak II in more detail, we used a slower dialysis
method of refolding that allowed analysis at different times
after initiation of the refolding. Two protein concentrations, 30
and 10 mg/ml, were analyzed in parallel. The composition of
the dialysis buffer was the same as that used in SEC elution
buffer, except that, to maximize the formation of oligomers, the
urea concentration was increased to 2 M (28). After 30-min
refolding, and at 30 mg/ml, both allelomorphs adopted predom-
inately oligomeric forms (peak II) with virtually no monomeric
protein present (peak III); this elution profile did not change
over the course of the experiment (Fig. 2A). Similar results
were obtained with a mixture (1:1) of Met129 and Val129 (data
not shown). The CD spectra of oligomers collected at 30 min
FIG. 1. Rapid refolding of recHuPrP90–231 with C-terminal His
tag from denatured/unfolded state by SEC-HPLC under condi-
tions that favored oligomers formation. recHuPrP90–231 Met129 (A),
recHuPrP90–231 Val129 (B), and an equimolar mixture (1:1) of Met129 and
Val129 in 6 M guanidine hydrochloride, 50 mM Tris-HCl, pH 7.2, at 30
mg/ml (C) were injected onto SEC and eluted with the equilibration
buffer (20 mM sodium acetate, 0.2 M NaCl, pH 3.7, 1 M urea, and 0.02%
sodium azide). D, the areas under the peaks were analyzed using Total
Chrome software 6.2 and the data used to construct the plot allowing a
direct comparison of the proportions of the peaks eluted from SEC
between Met129 and Val129 variants.
FIG. 2. SEC profiles of fractions of recHuPrP90–231 during time
course refolding into oligomer isoforms using dialysis method.
A and B are chromatograms of recHuPrP90–231 Met129 and Val129 at 30
and 10 mg/ml, respectively. Proteins in 6 M guanidine hydrochloride, 50
mM Tris-HCl, pH 7.2, were dialyzed against 20 mM sodium acetate, 0.2
M NaCl, pH 3.7, 2 M urea, and aliquots were withdrawn from the
dialysis cassette at the indicated time then injected onto SEC previ-
ously equilibrated in 20 mM sodium acetate, 0.2 M NaCl, pH 3.7, 1 M
urea, 0.02% sodium azide. C and D are CD spectra of Met129 and Val129,
respectively, recorded at the indicated times after manual collection of
the oligomer fraction that eluted in peak II from samples in A.
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and 1 h showed that the population was not dominated by
-sheet-rich structures but contained some -helical-rich pro-
tein (Fig. 2, C and D). However, by 4 h the CD spectra of the
protein contained in peak II from both allelomorphs were typ-
ical of proteins possessing high amounts of -sheet, and the
spectra remained constant thereafter.
In contrast, at 10 mg/ml (Fig. 2B) the kinetics of oligomer-
ization of PrP-Met129 were significantly different from those of
the PrP-Val129. The disappearance of aggregated proteins from
peak I occurred more rapidly in the Met129 variant than in the
Val129 variant, which suggests that, under oligomer-promoting
conditions, the aggregated material from PrP-Met129 has a
higher propensity to convert into oligomer than aggregated
protein from PrP-Val129. To test this, we took aggregated pro-
teins from peak I of PrP-Met129 and PP-Val129 from SEC at
time 0 and monitored their evolution over time by re-injecting
them onto the same SEC. Time course comparison between the
two allelomorphes clearly demonstrated the higher propensity
of the Met129 variant to oligomerize than the Val129 variant
(see supplementary Fig. 2). Virtually all aggregated PrP-
Met129 converted into oligomeric isoforms over a period of 12
days, whereas a substantial amount of PrP-Val129 remained as
aggregates. To investigate the behavior of monomeric species
in peak III under the same oligomeric-promoting conditions, we
compared the rate of oligomerization of the Met129 variant to
that of the Val129 variant collected from SEC at time 0. Time
course comparison between the two allelomorphs clearly re-
vealed that monomeric Met129 has a higher propensity to oli-
gomerize than monomeric Val129. This difference in oligomer-
ization rates was apparent after 2 days of incubation at room
temperature (see supplementary Fig. 2).
From these data we conclude that, under these conditions,
the Met129 variant has an intrinsically higher propensity to
form oligomer isoforms than the Val129. The high oligomeriza-
tion propensity of the methionine variant becomes even more
apparent under the highest protein concentration and rapid
refolding conditions. Since this is true for denatured, aggre-
gated, or natively folded monomeric protein, the higher propen-
sity of oligomerization is clearly independent of the starting
state of the protein.
The Oligomers of Both Met129 and Val129 Variants Are
Conformationally Heterogeneous and Show Different Kinetics
of Maturation—It has been shown that the oligomeric isoforms
of mouse and Syrian hamster PrP are formed of populations of
structurally heterogeneous proteins (26). RP-HPLC analysis
showed that reduced forms of recombinant mouse PrP existed
in multiple -sheet-rich isoforms with distinct retention times
(30, 31). Accordingly, we used RP-HPLC to investigate the
effect of the residue encoded at codon 129 on the composition of
the oligomer population that eluted from SEC in peak II. Ali-
quots of this fraction were incubated at room temperature in
SEC elution buffer (20 mM sodium acetate, 0.2 M NaCl, pH 3.7,
1 M urea, and 0.02% sodium azide) and analyzed at various
times (Fig. 3). After 2 days of incubation, the RP chromatogram
of PrP-Met129 showed two peaks with distinct retention times
(Fig. 3A); however, for PrP-Val129 only one major peak was
observed (Fig. 3B). A second peak could be seen only after 12
days of incubation. The two peaks were designated IIa and IIb,
with shorter and longer retention times, respectively. To rule
out the possibility that the two peaks represented unexpected
modification to the proteins, we analyzed them by mass spec-
trometry (Fig. 4). The deconvoluted mass spectra of PrP-Met129
IIa and PrP-Met129 IIb demonstrate that they represent pro-
teins of the same molecular mass (Fig. 4, A and B). Similarly,
the deconvoluted mass spectra of PrP-Val129 IIa and PrP-
Val129 IIb showed that they also represented proteins with
similar molecular masses (Fig. 4, C and D). From these anal-
yses we infer that no covalent differences are evident and that
the two peaks observed by RP-HPLC represent different con-
formations, with different amounts of hydrophobic residues
exposed at the protein surface.
FIG. 3. Time course analysis by RP-HPLC of oligomeric rec-
HuPrP90–231. Aliquots of recHuPrP90–231 Met129 (A) and recHuPrP90–231
Val129 (B) that were refolded by dialysis into oligomer isoforms for 4 h
then fractionated by SEC (see Fig. 2A) were incubated at room tempera-
ture in SEC elution buffer (20 mM sodium acetate, 0.2 M NaCl, pH 3.7, 1
M urea, 0.02% sodium azide) and anlalyzed by reversed-phase HPLC at
the indicated times. The elution was done with a linear gradient of H2O
0.1% trifluoroacetic acid to 95% acetonitrile  0.09% trifluoroacetic acid
over 25 min. For direct comparison of retention times, monomeric -hel-
ical and denatured (6 M guanidine hydrochloride) PrPs were analyzed by
RP-HPLC under the same conditions.
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Two important observations can be clearly made from re-
versed-phase chromatograms. First, the proportions of the two
forms of PrP-Met129 and PrP-Val129 were different; the propor-
tion of protein eluting in peak IIa was higher for PrP-Met129
after 12 days of incubation (Fig. 3, A versus B), while for
PrP-Val129 there was more protein that eluted in peak IIb.
Second, the proportions of the two peaks changed over time at
different rates for Met129 and Val129 variants. In particular, the
proportion of protein eluting in peak IIb decreased at a higher
rate in the oligomer of PrP-Met129 (Fig. 3A) than in the oli-
gomer of PrP-Val129 (Fig. 3B). Peak IIb of the oligomer from
both allelomorphs seemed to have a retention time similar to
that of the corresponding -helical monomers. Because RP-
HPLC uses differences in the hydrophobic properties to achieve
separation between bio-molecules, it can be concluded that the
protein population present in the highly retained peak IIb has
more surface-exposed hydrophobic residues than the protein
population present in peak IIa. Furthermore, the protein pop-
ulation present in peak IIb appears to undergo conversion to
become recruited into the population that eluted in peak IIa.
Over time, this conversion seemed to occur much quicker with
PrP-Met129 than with PrP-Val129 (Fig. 3, A versus B).
Because of the long storage time of both allelomorphs in SEC
elution buffer at room temperature, we have used mass spec-
trometry to assess the integrity of the samples (see supplemen-
tary Fig. 3). After 2 and 12 days of oligomerization, both allelo-
morphs had molecular masses that matched those predicted
from the amino acid sequences. However, after 30 days of
oligomerization, the deconvoluted mass spectra of both vari-
ants showed an additional species with a molecular mass that
corresponded to the cleavage of the N-terminal two residues
from the proteins (see supplementary Fig. 3). The two variants
showed the same level of cleavage that increased over time to
yield, 300 days later, proteins that were completely lacking two
residues from the N terminus (see supplementary Fig. 3). The
cleavage occurred in the peptide bond linking an aspartyl res-
idue to a prolyl residue (Fig. 5F). The lability of Asp-Pro bonds
under acidic conditions has been reported previously (32) and
provides a simple explanation for our observation. The cleavage
occurred at the same rate for both Met129 and Val129 variants
and at a region of the N terminus that was PK-sensitive (see
below) and, therefore, was unlikely to impact the differences
that were observed during oligomerization of the two
allelomorphs.
The Oligomers of Met129 and Val129 Show Similar Proteinase
K Resistance—Limited PK digestion has been used widely to
distinguish the disease isoform, PrPSc, from PrPC as well as to
probe differences between PrPSc strains (33, 34). We therefore
used limited PK digestion in combination with on-line capillary
HPLC mass spectrometry to probe differences between Met129
and Val129 variants during oligomerization. After treatment for
up to 60 min with a 1:24 ratio of PK to protein, capillary HPLC
mass spectrometry demonstrated that digestion of the oli-
gomers from both allelomorphs yielded a range of short pep-
tides that eluted before 20 min (insets in Fig. 5, A and B) that
were liberated from the N- and C-terminal His tag regions of
the protein. The central and C-terminal domains remained
intact and eluted after 20 min as two peaks from the reversed-
phase column (insets in Fig. 5, A and B). These polypeptides
separated into two peaks that started either from residues 117
or 135, respectively, as a result of differential cleavage within
the hydrophobic region (Fig. 5F). Comparison of deconvoluted
mass spectra of polypeptides starting at 117 between PrP-
Met129 (Fig. 5A) and PrP-Val129 (Fig. 5B) oligomers showed
FIG. 4. Nanospray mass spectrometry analysis of peaks IIa and IIb after 12 days of oligomerization. Peaks IIa and IIb that were
resolved by reversed-phase HPLC during the oligomerization of Met129 and Val129 were manually collected and immediately subjected to mass
spectrometry analysis. A and B are electrospray mass spectra and deconvoluted (see insets) mass spectra of peaks IIa and IIb, respectively, of the
Met129 oligomer. C and D are electrospray mass spectra and deconvoluted (see insets) mass spectra of peaks IIa and IIb, respectively, of Val129
oligomer.
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three major PK-resistant cores with matching cleavage sites for
each variant. The differences in masses (32 Da) between these
PK-resistant fragments were due only to the presence of me-
thionine or valine at position 129. Similarly, the comparison of
deconvoluted mass spectra of polypeptides that started at 135
between PrP-Met129 (Fig. 5C) and PrP-Val129 (Fig. 5D) oli-
gomers revealed four major PK-resistant polypeptides with
identical molecular masses for Met129 and Val129. Most, if not
all, of the C-terminal His tag remained PK-sensitive (Fig. 5F)
during oligomerization, indicating that it was unlikely to inter-
fere with the oligomerization process. SDS-PAGE separation of
the PK digests at various times of oligomerization (Fig. 5E)
provided additional evidence that oligomers from PrP-Met129
and PrP-Val129 have similar PK-resistant properties.
FIG. 5. Nanospray mass spectrometry and SDS-PAGE analysis of the proteinase K digests from oligomeric recHuPrP90–231. A,
deconvoluted mass spectrum of polypeptides eluting at 23.35 min from C-18 reversed-phase capillary HPLC (see inset) of Met129 oligomers. These
correspond to residues 117–225 (12678 Da), 117–232 (13488 Da), and 117–244 (14840 Da). B, deconvoluted mass spectrum of polypeptides eluting
at 22.90 min (see inset) of Val129 oligomers. These correspond to residues 117–225 (12 646 Da), 117–232 (13,456 Da), and 117–244 (14,808 Da). C,
deconvoluted mass spectrum of polypeptides eluting at 21.33 min (see inset in A) of Met129 oligomers. These correspond to residues 135–222 (10752
Da), 135–225 (11,114 Da), 135–232 (11,924 Da), and 135–244 (13,276). D, deconvoluted mass spectrum of polypeptides eluted at 21.55 min (see
inset in B) of Val129 oligomers. These correspond to residues 135–222 (10,752 Da), 135–225 (11,114 Da), 135–232 (11,924 Da), and 135–244 (13,276
Da). E, Coomassie-stained SDS-PAGE of limited proteinase K digests from Met129 and Val129 after 2, 12, and 140 days of oligomerization. The
digestion was carried out at 37 °C at the indicated incubation times with a ratio 1:24 PK to protein. F, the PK-resistant fragments that were
identified by mass spectrometry are overlaid on the amino acid sequence of human PrP Met/Val129. The residues that were introduced into the
recombinant HuPrP for cloning and purification purposes are indicated in green at the N terminus and in blue at the C terminus.
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DISCUSSION
In this work we show that the polymorphism at codon 129
affects the kinetics of oligomerization that leads to non-native
isoforms of human prion protein. Starting from an unfolded
state and when forced rapidly to adopt the oligomeric form
under low pH and at high protein concentration, the Met129
variant clearly exhibited a preference for the oligomeric state,
whereas the Val129 variant favored the -helical-rich, mono-
meric state. The apparent molecular mass of the oligomers
from both PrP variants was estimated to be around 400 kDa,
close to that reported previously (26). We have ruled out the
possibility that the denatured starting protein contained any
oligomeric forms of PrP by SEC analysis under denaturing
conditions using 6 M guanidine hydrochloride, 50 mM Tris-HCl,
pH 7.2, as elution buffer. Indeed the chromatograms showed
only a monomeric population of both PrP variants (see supple-
mentary Fig. 4). How then does residue 129 influence this
folding behavior? The first clue can be derived from the solution
structure of human PrP determined by NMR (35). Residue 129
lies within the first -strand (residues 128–131) in human PrP.
Riek et al. (36) proposed that this short -sheet might be a
“nucleation site” for a conformational transition from PrPC to
PrPSc that could include the loops connecting the -sheet to the
first helix. Prion peptide models have also indicated the possi-
ble involvement of the region containing the first -strand in
the conformational switch of PrP (37, 38). To our knowledge
there is no published structure of the Val129 variant of human
PrP; however, molecular dynamic simulations of Syrian ham-
ster PrP90–231 at neutral pH showed that when a valine residue
was present at position 129 instead of a methionine residue,
the proportion of protein with a three-stranded, antiparallel
-sheet structure increased from 0 to 23% (39). The three
-strands spanned residues 115–116, 119–122, and 129–130
without affecting the thermodynamic stability of PrP, as was
demonstrated experimentally (23). Molecular dynamic simula-
tions of Syrian hamster PrP109–219 at low pH revealed that
regions around -strand 1 and -strand 2 were potential sites
for conversion to -structures (25). In particular, the first
-strand served as a structural nucleus for the formation of
new, and propagation of existing, -like structures (25). The
interactions between Met129 and Val122 and between Tyr128
and Tyr162 illustrated the role of tertiary interactions between
side chains nucleating secondary structure formation, as has
been observed for helix formation in barnase (40).
Our experimental data show that, under conditions that
favor rapid formation of oligomers, SEC can be used to parti-
tion protein folded into aggregated, monomeric and oligomeric
states so that differences in folding of Met129 and Val129 vari-
ants become clear. It has been shown that folding of recombi-
nant, murine prion protein into -helix-rich conformation is
extremely rapid (41) and is under kinetic control (28). We show
in this work that the propensity of recombinant human prion
protein to fold into monomeric -helical-rich population is in-
creased when residue 129 was occupied by a valine. However,
when the same position is occupied by methionine a tendency
for oligomerization can be observed, with comparatively little
monomeric -helical-rich population. These differences in fold-
ing behavior can be explained by a fundamental event in pro-
tein folding, which is driven by a small number of specific
residues involved in the formation of a well defined, specific
nucleus that then allows the rest of the structure to coalesce
efficiently around it (42, 43). The high -sheet propensity of
valine residues as compared with methionine residues (44, 45)
makes PrP in which valine is present at residue 129 more
favorable to adopt the native local -sheet that would tempo-
rarily stabilize the Val129 allelomorph in the monomeric
-helical PrP.
Differences between the oligomers formed from Met129 and
Val129 could be seen when we explored the hydrophobicity of
the oligomers as they evolved over time. These differences were
consistent with early events that were observed during the
rapid misfolding process. That is, the proportion of oligomer
subunits with hydrophobic properties resembling those of the
-monomer was higher in PrP-Val129 than in the PrP-Met129.
Over the course of several weeks of incubation, the oligomer-
ization process in both variants occurred at the expense of the
-helical-like population that became a substrate for oligomer
recruitment (28, 46). The presence of the -helical-like species
in the oligomer reflected the heterogeneous nature of this non-
native form of PrP. This finding was consistent with the pre-
viously published supra-molecular electrospray ionization
mass spectrometry results (26). On the basis of these observa-
tions we propose a model (Fig. 6) that depicts the formation of
non-native -oligomers in vitro. Under appropriate conditions
(low pH and high protein concentration) the acquisition of this
non-native form can happen from either denatured, aggre-
FIG. 6. Schematic model illustrat-
ing in vitro formation and matura-
tion of oligomer isoforms of
recHuPrP90–231 Met129 and Val129. Un-
der appropriate conditions (low pH and
high protein concentration) the acquisi-
tion of non-native form can happen from
either denatured, aggregated, or native
forms and involves two steps: a rapid oli-
gomerization phase followed by a slow
maturation phase characterized by a
structural rearrangement of the oli-
gomers. The presence of a methionine at
codon 129 affects both the kinetics of oli-
gomerization and those of the maturation
phase.
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gated, or native forms and involves two steps: a rapid oligomer-
ization phase followed by a slow maturation phase character-
ized by a structural rearrangement of the oligomers. The
presence of a methionine at codon 129 affects both the kinetics
of oligomerization and those of the maturation phase.
A hallmark of the disease isoform, PrPSc, is its partial resist-
ance to proteinase K digestion compared with normal cellular
PrP. This property has also been used to probe differences
between PrPSc conformations. We found that once oligomers
from both allelomorphs are formed they show similar protein-
ase K resistance that does not change throughout the oligomer
maturation process. This indicates that if one relies solely on
PK digestion to investigate PrP conformations, one could miss
the detection of dynamic conformational changes influenced by
the polymorphism at codon 129 in human PrP during disease
pathogenesis. A similar PK cleavage site (starting at residue
117) in the protease-resistant core of the oligomers from both
human PrP variants has been reported for recombinant mouse
PrP23–231 (47). It is important to emphasize that this PK cleav-
age site is not the same as the termini around codon 90 found
for authentic PrPSc (48).
It has been reported that two mutations in -synuclein that
are linked to early-onset Parkinson’s disease can accelerate the
oligomerization but not fibrilization suggesting that formation
of nonfibrillar oligomer is likely to be critical in disease patho-
genesis (49). There is no evidence so far that these -oligomers
exist in vivo or can directly cause prion diseases either alone or
with the help of other factors. The high affinity and newly
reported ligands that we have isolated in our laboratory (50,
51) would help investigating the presence in vivo of the -oli-
gomers. The observed differences in the misfolding behavior
between Met129 and Val129 variants could provide a kinetic
explanation to the observed high susceptibility of individuals
that are methionine homozygote to sporadic as well as to var-
iant CJD. The attempt to model a heterozygote situation by
mixing Met129/Val129 (1:1) and allowing the rapid refolding to
occur has yielded some promising results in that the amount of
oligomers formed was reduced by 30% as compared with the
homozoygote-like situation in the Met129 alone, indicating cer-
tain degree of inhibition of the oligomerization in the
heterozygote.
Phylogenetically, methionine is the ancestral amino acid at
codon 129 (52), and Val129 is a mutation found in humans.
Worldwide PRNP haplotype diversity and coding allele fre-
quencies suggest that strong balancing selection at this locus
occurred during the evolution of modern human and made
heterozygosity at PRNP a significant selective advantage (53).
Our data could provide a mechanism based on prion protein
folding properties as an additional selective pressure against,
particularly, Met129 homozygosity.
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